130 related articles for article (PubMed ID: 22960860)
1. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors.
Karami-Tehrani F; Moeinifard M; Aghaei M; Atri M
Arch Med Res; 2012 Aug; 43(6):470-5. PubMed ID: 22960860
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.
Nagasaki S; Nakano Y; Masuda M; Ono K; Miki Y; Shibahara Y; Sasano H
BJU Int; 2012 Mar; 109(6):934-40. PubMed ID: 21736695
[TBL] [Abstract][Full Text] [Related]
3. Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissues.
Uckert S; Ellinghaus P; Albrecht K; Jonas U; Oelke M
J Sex Med; 2007 Nov; 4(6):1604-9. PubMed ID: 17888073
[TBL] [Abstract][Full Text] [Related]
4. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains.
Reyes-Irisarri E; Markerink-Van Ittersum M; Mengod G; de Vente J
Eur J Neurosci; 2007 Jun; 25(11):3332-8. PubMed ID: 17553001
[TBL] [Abstract][Full Text] [Related]
5. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
6. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
[TBL] [Abstract][Full Text] [Related]
7. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study.
Oelke M; Hedlund P; Albrecht K; Ellinghaus P; Stief CG; Jonas U; Andersson KE; Uckert S
Urology; 2006 May; 67(5):1111-6. PubMed ID: 16635522
[TBL] [Abstract][Full Text] [Related]
8. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain.
Van Staveren WC; Steinbusch HW; Markerink-Van Ittersum M; Repaske DR; Goy MF; Kotera J; Omori K; Beavo JA; De Vente J
J Comp Neurol; 2003 Dec; 467(4):566-80. PubMed ID: 14624489
[TBL] [Abstract][Full Text] [Related]
9. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues.
Singer AL; Sherwin RP; Dunn AS; Appleman MM
Cancer Res; 1976 Jan; 36(1):60-6. PubMed ID: 174814
[TBL] [Abstract][Full Text] [Related]
10. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
Johnson WB; Katugampola S; Able S; Napier C; Harding SE
Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
[TBL] [Abstract][Full Text] [Related]
11. Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy.
Catalano S; Campana A; Giordano C; Győrffy B; Tarallo R; Rinaldi A; Bruno G; Ferraro A; Romeo F; Lanzino M; Naro F; Bonofiglio D; Andò S; Barone I
Clin Cancer Res; 2016 May; 22(9):2271-82. PubMed ID: 26667489
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5.
Schankin CJ; Kruse LS; Reinisch VM; Jungmann S; Kristensen JC; Grau S; Ferrari U; Sinicina I; Goldbrunner R; Straube A; Kruuse C
Headache; 2010 Mar; 50(3):431-41. PubMed ID: 19751368
[TBL] [Abstract][Full Text] [Related]
13. Implementation of micromethods to resolve problems of human breast tumor heterogeneity in analysis of cyclic 3':5'-nucleotide phosphodiesterase.
Larner EH; Rutherford CL
Cancer Res; 1982 May; 42(5):1661-8. PubMed ID: 6279280
[TBL] [Abstract][Full Text] [Related]
14. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
15. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
[TBL] [Abstract][Full Text] [Related]
16. Expression and role of phosphodiesterase 5 in human malignant melanoma cell line.
Murata T; Shimizu K; Watanabe Y; Morita H; Sekida M; Tagawa T
Anticancer Res; 2010 Feb; 30(2):355-8. PubMed ID: 20332439
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468.
Saravani R; Karami-Tehrani F; Hashemi M; Aghaei M; Edalat R
Cell Prolif; 2012 Jun; 45(3):199-206. PubMed ID: 22469131
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
19. Role of PDE9 in Cognition.
Dorner-Ciossek C; Kroker KS; Rosenbrock H
Adv Neurobiol; 2017; 17():231-254. PubMed ID: 28956335
[TBL] [Abstract][Full Text] [Related]
20. Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
Kapui Z; Schaeffer P; Mikus EG; Boronkay E; Gyürky J; Herbert JM; Pascal M
Arzneimittelforschung; 1999 Aug; 49(8):685-93. PubMed ID: 10483515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
